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MaBACKGROUND The everolimus-eluting bioresorbable vascular scaffold (BVS) is designed to achieve results comparable
to metallic drug-eluting stents at 1 year, with improved long-term outcomes. Whether the 1-year clinical and angio-
graphic results of BVS are noninferior to current-generation drug-eluting stents has not been established.
OBJECTIVES This study sought to evaluate the angiographic efﬁcacy and clinical safety and effectiveness of BVS in a
randomized trial designed to enable approval of the BVS in China.
METHODS Eligible patients with 1 or 2 de novo native coronary artery lesions were randomized to BVS or cobalt-
chromium everolimus-eluting stents (CoCr-EES) in a 1:1 ratio stratiﬁed by diabetes and the number of lesions treated.
Angiographic and clinical follow-up were planned at 1 year in all patients. The primary endpoint was angiographic in-
segment late loss (LL), powered for noninferiority with a margin of 0.15 mm.
RESULTS A total of 480 patients were randomized (241 BVS vs. 239 CoCr-EES) at 24 sites. Acute clinical device success
(98.0% vs. 99.6%; p ¼ 0.22) and procedural success (97.0% and 98.3%; p ¼ 0.37) were comparable in BVS- and CoCr-
EES–treated patients, respectively. The primary endpoint of in-segment LL at 1 year was 0.19  0.38 mm for BVS versus
0.13  0.38 mm for CoCr-EES; the 1-sided 97.5% upper conﬁdence limit of the difference was 0.14 mm, achieving
noninferiority of BVS compared with CoCr-EES (pnoninferiority ¼ 0.01). BVS and CoCr-EES also had similar 1-year rates of
target lesion failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization;
3.4% vs. 4.2%, respectively; p ¼ 0.62) and deﬁnite/probable scaffold/stent thrombosis (0.4% vs. 0.0%, respectively;
p ¼ 1.00).
CONCLUSIONS In the present multicenter randomized trial, BVS was noninferior to CoCr-EES for the primary
endpoint of in-segment LL at 1 year. (A Clinical Evaluation of Absorb Bioresorbable Vascular Scaffold [Absorb BVS]
System in Chinese Population—ABSORB CHINA Randomized Controlled Trial [RCT]; NCT01923740)
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AB BR E V I A T I O N S
AND ACRONYM S
ABR = angiographic binary
restenosis
BVS = bioresorbable vascular
scaffold(s)
CoCr-EES = cobalt-chromium
everolimus-eluting stent(s)
DS = diameter stenosis
LL = late loss
MI = myocardial infarction
MLD = minimum lumen
diameter
PoCE = patient-oriented
osite endpoint
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2299C ardiovascular disease is the leading cause ofdeath in China, accounting for 41% of alldeaths (1,2). Exponential increases in percu-
taneous coronary intervention (PCI) in China have
been observed over the last 10 years (2), with approx-
imately 450,000 PCI cases performed in 2013 (3). The
everolimus-eluting bioresorbable vascular scaffold
(BVS) (Absorb, Abbott Vascular, Santa Clara, Califor-
nia) offers a new PCI option for this growing patient
population.
The BVS is constructed from a poly L-lactide
backbone coated with a bioresorbable polymeric
poly (D,L-lactide) layer containing everolimus, and it
was designed to provide comparable radial strength
and antirestenotic efﬁcacy to metallic drug-eluting
stents (DES) in the ﬁrst year. The degradation of poly
L-lactide in vivo is governed by bulk erosion beginning
with a decline in molecular weight, followed by
mass loss via hydrolysis upon exposure to water over
time (4,5). Complete bioresorption at approximately
3 years may then provide unique long-term beneﬁts
not possible with a permanent metallic stent,
including restoration of physiological vasomotion and
late adaptive remodeling. Real-world registries have
shown favorable outcomes of BVS in simple and com-
plex coronary anatomy with proper implantation
technique (6,7).SEE PAGE 2310Whether BVS is noninferior to current-generation
DES within 1 year and whether BVS has late clinical
advantages to metallic DES can only be answered by
adequately powered randomized trials. The ABSORB
II randomized trial suggested comparable clinical
outcomes between BVS and cobalt-chromium ever-
olimus-eluting stents (CoCr-EES) (Xience V, Abbott
Vascular) in 501 randomized patients at 1 year (8),
although routine angiographic follow-up was not
performed in this study. The pivotal, randomized
ABSORB China trial sought to establish comparable
angiographic efﬁcacy and clinical safety and effec-
tiveness between BVS and CoCr-EES to enable regu-
latory approval of BVS in China. The present report
describes the 1-year principal outcomes from the
ABSORB China randomized trial.
METHODS
STUDY DESIGN AND PATIENT POPULATION. ABSORB
China is a prospective, randomized, active-controlled,
open-label, multicenter trial designed to evaluate the
safety and efﬁcacy of BVS compared with CoCr-EES.
The study was performed in compliance with the
Declaration of Helsinki and Good Clinical Practiceguidelines of the China Food and Drug
Administration. All patients signed written
informed consent before randomization.
Eligible patients were age $18 years with
evidence of myocardial ischemia and suit-
ability for elective (nonemergent) PCI, with a
maximum of 2 de novo coronary artery le-
sions with reference vessel diameter 2.5 to
3.75 mm and length #24 mm as assessed by
online quantitative coronary angiography
(QCA) or visual estimation. In the case of
multiple target lesions, each needed to be in a
different epicardial vessel and each must
meet eligibility criteria. In addition, 1
nontarget lesion in a nontarget vessel was
allowed to be treated during the index procedure.
Treatment of the nontarget lesion was required
before randomization, and had to be successful and
uncomplicated for randomization to proceed. Pa-
tients with recent myocardial infarction (MI) without
biomarker return to normal, unstable cardiac ar-
rhythmias and left ventricular ejection fraction <30%
were excluded. Patients were also excluded for prior
PCI in the target vessel within the past 12 months or in
a nontarget vessel within the previous 30 days, or if
future staged PCI either in a target vessel or nontarget
vessel was planned. Left main stenoses, bifurcation
lesions with a side branch $2.0 mm diameter or $50%
diameter stenosis (DS) or requiring guidewire pro-
tection, ostial lesions, lesions with moderate or heavy
calciﬁcation, myocardial bridges, and thrombus were
also not eligible. Additional inclusion and exclusion
criteria are detailed in the Online Appendix.
RANDOMIZATION AND ENROLLMENT. A total of
480 eligible patients who provided written informed
consent were randomized in a 1:1 ratio to receive
BVS or CoCr-EES at 24 sites in China. Randomization
was stratiﬁed by diabetes status and the planned
number of treated lesions, which included 3 options:
single-target lesion, dual-target lesion, and 1 target
lesion and 1 nontarget lesion. Randomization was
performed via an interactive voice response system
or an interactive web response system. Patients
were considered enrolled in the trial at the time of
randomization.
TREATMENT STRATEGY, MEDICATIONS, AND FOLLOW-UP.
Pre-dilation was required, with post-dilation per
investigator discretion. Each target lesion had to be
covered by a single study stent, although use of a
second device as randomized was allowed for edge
dissection or other procedural issues. A loading
dose of aspirin ($300 mg) and either clopidogrel
($300 mg) or ticagrelor (180 mg) 6 to 24 h before the
comp
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2300index procedure was required. The P2Y12 inhibitor
loading dose could be omitted if the patient was on
chronic clopidogrel or ticagrelor therapy ($3 days),
unless an acute coronary syndrome was present.
Following PCI, aspirin 100 mg daily for at least 5 years
was prescribed, with clopidogrel (75 mg daily) or
ticagrelor (90 mg twice a day) for a minimum of 12
months. Prasugrel was not available for use during
this study.
Clinical follow-up was planned at 30 days, 6
months, 9 months, and at 1, 2, 3, 4, and 5 years post-
procedure. Routine follow-up angiography was plan-
ned in all patients at 1 year (28 days).
ENDPOINTS AND DEFINITIONS. The trial was
designed to examine whether BVS was noninferior to
CoCr-EES for the primary endpoint of angiographic in-
segment late loss (LL), deﬁned as the change in mini-
mal lumen diameter (MLD) from post-procedure to
1 year. In-segment was deﬁned as the stent/scaffold
length plus proximal and distal 5-mm margins. If a
patient had a TLR>30 days post-procedure, but before
his or her scheduled angiographic follow-up, the event
angiogram was used for the primary endpoint anal-
ysis. Details of angiographic and clinical secondary
endpoints are provided in the Online Appendix.
Acute device success was deﬁned as successful
delivery and deployment of the assigned device and
withdrawal of the catheter with <30% residual ste-
nosis by angiography, whether or not bailout was
required. Acute procedural success was deﬁned as
device success without occurrence of in-hospital
cardiac death, target vessel [TV]-MI, or TLR; in the
case of dual target lesions, both lesions must be suc-
cessfully treated. Most clinical endpoint deﬁnitions,
including stent/scaffold thrombosis, were on the basis
of the Academic Research Consortium deﬁnitions
(9). Periprocedural non–Q-wave MI, however, was
deﬁned as a rise in post-PCI creatine kinase (CK)-MB to
>5 the upper reference limit (URL) (10), similar to the
deﬁnition used in the ABSORB III U.S. pivotal trial,
which ran concurrently with ABSORB China. The
device-oriented composite endpoint was target
lesion failure (the composite of cardiac death, TV-MI,
or ischemia-driven target lesion revascularization
[ID-TLR]). The patient-oriented composite endpoint
(PoCE) was the composite of all-cause death, all MI or
all revascularization. Detailed deﬁnitions of acute
device and procedural success, clinical composite
endpoints, and angiographic endpoints are provided
in the Online Appendix.
ANALYSIS POPULATIONS. The primary angiographic
endpoint of in-segment LL was analyzed in the per-
treatment evaluable (PTE) population, consisting
of patients who received only the study device(BVS or CoCr-EES as treated), and who had no
pre-speciﬁed protocol deviations. All clinical and
angiographic endpoints, including a secondary an-
alysis of the in-segment LL, were reported in the
intention-to-treat (ITT) population, consisting of all
randomized patients. For the ITT analysis, patients
remained in their assigned group, regardless of de-
vice implant cross-overs.
TRIAL MANAGEMENT. Clinical endpoint events were
adjudicated by an independent clinical events com-
mittee, blinded to device assignment. QCA data were
assessed by an independent angiographic core labo-
ratory. A data safety and monitoring board reviewed
the cumulative safety data from the trial at pre-
speciﬁed intervals. On-site monitoring was per-
formed on 100% of data. The study organization,
investigators, and enrollment per site appears in
the Online Appendix. The study was sponsored by
Abbott Vascular and is registered on ClinicalTrials.gov
(NCT01923740).
STATISTICAL ANALYSIS. A noninferiority margin of
0.15 mm was chosen, a more conservative delta than
that used to evaluate the CoCr-EES compared with a
paclitaxel-eluting DES in the SPIRIT III (Clinical
Evaluation of the XIENCE V Everolimus Eluting Cor-
onary Stent System in the Treatment of Patients with
De Novo native Coronary Artery Lesions Trial) (11).
Assuming no difference in the mean in-segment LL,
an SD of 0.47 mm for both devices, and an anticipated
70% angiographic follow-up rate, randomizing 480
patients would provide 80% power to demonstrate
noninferiority of BVS to CoCr-EES with a 1-sided
alpha of 2.5%.
The primary endpoint hypothesis testing was pre-
speciﬁed to be performed on a per-subject basis, in
which the LL of 2 target lesions would be averaged.
All follow-up angiographic endpoints were also
evaluated in both PTE and ITT populations, with
generalized estimating equations used to adjust for
within-patient correlations.
The 1-year clinical follow-upwas performed at 365
28 days. All events occurring before 393 days were
included in the 1-year categorical rates, even if they
occurred after routine 1-year angiographic follow-up.
Continuous variables are presented as mean  SD
andwere compared by Student t tests. Binary variables
are presented as counts and percentages, and were
compared by Pearson’s chi-square test when Co-
chran’s rule was met; otherwise, the Fisher exact
test was used. The noninferiority test was on the basis
of the asymptotic Z test. The 95% conﬁdence interval
of the difference between 2 treatment arms was
calculated by normal approximation for continuous
variables and by the Newcombe score method for
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2301binary variables. Time to ﬁrst event curves were
plotted using Kaplan-Meier estimates and were
compared with the log-rank test. All statistical ana-
lyses were carried out using SAS version 9.2 (SAS
Institute, Cary, North Carolina).
RESULTS
PATIENTS AND PROCEDURAL RESULTS. Between
July 31, 2013, and March 13, 2014, 480 patients were
randomized at 24 sites in China (241 to BVS and 239 to
CoCr-EES). Subject disposition is shown in Figure 1.FIGURE 1 Study Design and Patient Disposition
Random
N
BVS
N=241
Withdrew ICF before
study device attempt: 3
In–hospital
Clinical Follow–up: N=238
30 Days
Clinical Follow–up: N=238
180 Days
Clinical Follow–up: N=238
270 Days
Clinical Follow–up: N=238
365 Days
Clinical Follow–up: N=238
Angiography Follow–up:
N=208 (ITT)
N=200 (PTE)
BVS ¼ bioresorbable vascular scaffold; CoCr-EES ¼ cobalt-chromium ev
PTE ¼ per-treatment-evaluable.Five patients withdrew consent before use of any
study device. Four crossovers occurred, 2 in each
group. One crossover from BVS to CoCr-EES occurred
after the BVS failed to cross the target lesion, and the
other was due to absence of the appropriate BVS de-
vice size at the time of randomization. The 2 cross-
overs from CoCr-EES to BVS were due to site error. Of
the 480 patients in the ITT population, 20 did not
meet PTE criteria: 5 were subject withdrawals before
any study device attempts during the index proce-
dure (3 BVS and 2 CoCr-EES); 13 were subjects with at
least 1 pre-speciﬁed protocol deviation (9 BVS and 4ization (ITT)
=480
CoCr-EES
N=239
Withdrew ICF before
study device attempt: 2
In–hospital
Clinical Follow–up: N=237
30 Days
Clinical Follow–up: N=237
180 Days
Clinical Follow–up: N=237
270 Days
Clinical Follow–up: N=237
365 Days
Clinical Follow–up: N=237
Angiography Follow–up:
N=199 (ITT)
N=195 (PTE)
erolimus-eluting stent; ICF ¼ informed consent form; ITT ¼ intention-to-treat;
TABLE 1 Baseline Patient and Target Lesion Characteristics
(Intention-to-Treat Population)
BVS CoCr-EES
Patient-level data
n 238 237
Age, yrs 57.2  11.4 57.6  9.6
Male 71.8 (171/238) 72.6 (172/237)
Body mass index, kg/m2 25.2  3.4 25.3  3.2
Current tobacco use 32.8 (78/238) 35.4 (84/237)
Hypertension 58.8 (140/238) 60.3 (143/237)
Hyperlipidemia 42.4 (101/238) 38.4 (91/237)
All diabetes 25.2 (60/238) 23.2 (55/237)
Insulin-treated 9.7 (23/238) 7.6 (18/237)
Prior coronary intervention 9.7 (23/238) 8.0 (19/237)
Prior myocardial infarction 16.8 (40/238) 16.0 (38/237)
Stable angina 22.3 (53/248) 16.9 (40/237)
Unstable angina 64.7 (154/238) 64.1 (152/237)
Recent myocardial infarction 7.6 (18/238) 11.8 (28/237)
Post-infarction angina 1.7 (4/238) 1.7 (4/237)
Silent ischemia 3.8 (9/238) 5.5 (13/237)
Single-vessel disease 63.0 (150/238) 56.5 (134/237)
Double-vessel disease 19.3 (46/238) 21.9 (52/237)
Triple-vessel disease 17.6 (42/238) 21.5 (51/237)
Target vessel and lesion-level data
Lesions, n 251 252
Left anterior descending artery 55.4 (139/251) 52.4 (132/252)
Left circumﬂex artery 19.5 (49/251) 24.2 (61/252)
Right coronary artery 25.1 (63/251) 23.4 (59/252)
Calciﬁcation (moderate or severe) 17.5 (44/251) 15.5 (39/251)
Eccentric 78.5 (197/251) 75.1 (187/249)
Bifurcation 50.2 (126/251) 48.6 (122/251)
ACC/AHA lesion class
A 4.0 (10/251) 5.6 (14/251)
B1 21.1 (53/251) 22.3 (56/251)
B2 47.8 (120/251) 50.2 (126/251)
C 27.1 (68/251) 21.9 (55/251)
Values are mean  SD or % (n/N) unless otherwise indicated. There were no signiﬁcant differ-
ences between groups.
ACC/AHA ¼ American College of Cardiology/American Heart Association; BVS ¼ bioresorbable
vascular scaffold; CoCr-EES ¼ cobalt-chromium everolimus-eluting stent.
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2302CoCr-EES); 1 was the BVS subject who had no study
device implanted at the target lesion (treated with
CoCr-EES due to BVS product unavailability at the
site); and 1 was a BVS subject treated with both a BVS
and CoCr-EES at the target lesion (the latter for bail-
out after a BVS edge dissection). The PTE popula-
tion thus consisted of 460 patients (228 BVS and 232
CoCr-EES).
Patient demographics, risk factors, and lesion
characteristics at baseline were well-balanced be-
tween the BVS and CoCr-EES arms (Table 1). Most BVS
and CoCr-EES patients (94.5% and 93.7%, respec-
tively) had a single target lesion treated, and 8.4%
and 6.8%, respectively, had a single nontarget lesion
treated (Table 2). Device diameters and length were
also similar between groups. Use of intravascularimaging was infrequent. Device post-dilation was
performed in a slightly greater proportion of BVS
cases. Acute device and procedural success rates were
similar with BVS and CoCr-EES, as was discharge
medication use (Table 2).
Baseline lesion length, reference vessel diameter,
MLD, and %DS were balanced between groups
(Table 3). The post-procedure in-segment MLD, acute
gain, and %DS were similar with both devices. How-
ever, within the device the post-procedural MLD and
acute gain were lower with BVS compared with CoCr-
EES, and the %DS was slightly greater.
1-YEAR ANGIOGRAPHIC OUTCOMES. The 1-year
angiographic follow-up data was available in 86.3%
(208 of 241) of BVS and 83.3% (199 of 239) of CoCr-EES
patients per ITT, and in 87.7% (200 of 228) BVS and
84.1% (195 of 232) CoCr-EES patients per PTE. The
primary endpoint of 1-year in-segment LL in the
PTE population based on per-subject analysis was
0.19  0.38 mm with BVS versus 0.13  0.38 mm with
CoCr-EES. The 1-sided 97.5% upper conﬁdence limit
of the observed 0.06-mm difference is 0.14 mm,
which is below the noninferiority margin of 0.15 mm
(pnoninferiority ¼ 0.01). In the per-subject analysis in
the ITT population, BVS was also noninferior to CoCr-
EES for 1-year in-segment LL (Table 4). When
analyzed on a per-lesion analysis, BVS was also non-
inferior to CoCr-EES in both the PTE and ITT pop-
ulations (Table 4).
The 1-year angiographic results by ITT are reported
in Table 3, and late loss cumulative frequency distri-
bution curves are shown in the Central Illustration. At
1-year, BVS had a slightly smaller MLD and larger %DS
compared with CoCr-EES within the device, but
similar in-segment measures. Angiographic binary
restenosis (ABR) rates at 1 year were low and com-
parable with both devices, whether measured in-
device or -segment.
1-YEAR CLINICAL OUTCOMES. The 1-year clinical
follow-up was completed in 98.8% (238 of 241) of BVS
patients and in 99.2% (237 of 239) of CoCr-EES pa-
tients. At 1 year, 99.6% BVS and 96.2% CoCr-EES pa-
tients were taking aspirin (p ¼ 0.02), and 98.3% BVS
and 95.8% CoCr-EES patients were taking a P2Y12 in-
hibitor (p ¼ 0.10).
As shown in Table 5 and Figure 2, the 1-year rates of
all evaluated composite safety and efﬁcacy measures
were not signiﬁcantly different between BVS and
CoCr-EES. Similarly, the component measures of
these endpoints were similar with both devices,
other than lower 1-year all-cause mortality with BVS
(0% vs. 2.1%; p ¼ 0.03). The periprocedural MI rates
were low and similar between BVS and CoCr-EES by
the protocol deﬁnition (CK-MB >5 URL; 1.3% vs.
TABLE 2 Procedural Parameters and Discharge Medications, Intention-To-Treat Population
BVS CoCr-EES Difference (95% CI) p Value
Patient-level data
n 238 237
Number of target lesions treated 1.1  0.2 1.1  0.2 0.0 (0.1 to 0.0) 0.69
1 target lesion treated 94.5 (225/238) 93.7 (222/237) 0.87 (3.5 to 5.3) 0.69
2 target lesions treated 5.5 (13/238) 6.3 (15/237) 0.9 (5.3 to 3.5) 0.69
Additional nontarget lesion treated 8.4 (20/238) 6.8 (16/237) 1.7 (3.2 to 6.6) 0.50
Intravascular ultrasound imaging* 0.4 (1/238) 0.4 (1/239) 0.0 (2.0 to 2.0) 1.00
Clinical procedure success 97.0 (230/237) 98.3 (230/234) 1.24 (4.4 to 1.8) 0.37
Discharge medications
Aspirin 100.0 (236/236) 100.0 (237/237) 0.0 (1.6 to 1.6) 1.00
P2Y12 inhibitor, any 100.0 (238/238) 100.0 (237/237) 0.0 (1.6 to 1.6) 1.00
Clopidogrel 98.7 (235/238) 99.2 (235/237) 0.4 (2.9 to 1.9) 1.00
Ticagrelor 1.3 (3/238) 0.8 (2/237) 0.4 (1.9 to 2.9) 1.00
Lesion-level data
Lesions, n 251 252
Pre-dilation 99.6 (250/251) 98.0 (247/252) 1.6 (0.6 to 4.2) 0.22
Post-dilation 63.0 (162/257) 54.4 (141/259) 8.6 (0.1 to 16.9) 0.05
Bailout stenting during procedure 2.0 (5/251) 2.8 (7/252) 0.8 (3.9 to 2.2) 0.56
Total study device length, mm 22.8  6.7 22.3  5.8 0.5 (0.6 to 1.6) 0.80
Maximum study device diameter, mm 3.1  0.4 3.1  0.4 0.01 (0.1 to 0.1) 0.83
Maximum balloon diameter, mm
Pre-dilation 2.8  0.4 2.7  0.4 0.1 (0.01 to 0.1) 0.07
Post-dilation 3.3  0.4 3.2  0.4 0.04 (0.1 to 0.1) 0.38
Maximum balloon pressure
Pre-dilation 12.4  3.3 11.8  3.3 0.6 (0.0 to 1.2) 0.04
Deployment 12.8  2.4 12.8  2.8 0.1 (0.5 to 0.4) 0.71
Post-dilation 16.8  3.8 16.9  3.4 0.2 (1.0 to 0.6) 0.69
Clinical device success 98.0 (245/250) 99.6 (248/249) 1.6 (4.2 to 0.6) 0.22
Values are mean  SD or % (n/N) unless otherwise indicated. *No other intravascular imaging devices were used.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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23030.4%, respectively; p ¼ 0.62), or if a more sensitive
deﬁnition (CK-MB >3 URL; 1.8% vs. 0.9% respec-
tively; p ¼ 0.69) or less sensitive deﬁnition (CK-MB
>10 URL; 0.4% vs. 0.0%, respectively; p ¼ 1.0) was
used.
There were no deﬁnite scaffold or stent thrombo-
ses during the 1-year follow-up period. One BVS pa-
tient developed an MI within the distribution of the
target vessel 15 days post-procedure that was initially
treated medically. Angiography performed 6 days
later demonstrated 20.7% and 21.6% in-device
and -segment diameter stenoses, respectively, at the
target lesion site, without thrombus evident. None-
theless, this event was adjudicated as a probable
scaffold thrombosis. There were no other thrombosis
events. Thus, the 1-year rate of deﬁnite/probable
scaffold/stent thrombosis was 0.4% with BVS and 0%
with CoCr-EES (p ¼ 1.00).
SIDE BRANCH ANALYSIS. Although bifurcations with
a side branch $2 mm diameter or $50% DS or
requiring guidewire protection were excluded fromenrollment, 126 BVS and 122 CoCr-EES target lesions
in the study were classiﬁed as bifurcation lesions by
the core laboratory using a more sensitive 1.5-mm
side branch diameter cut-off. Core laboratory anal-
ysis was completed in 124 and 116 of these lesions,
respectively, of which 31 (25.0%) and 22 (19.0%) were
true bifurcation lesions (Medina 1:1:1, 1:0:1, or 0:1:1).
Side branch TIMI (Thrombolysis In Myocardial
Infarction)-3 ﬂow was present in 96.0% of BVS and
97.4% of CoCr-EES bifurcation lesions pre-procedure
(p ¼ 0.72), and in 95.2% of BVS vs. 95.7% of CoCr-
EES bifurcation lesions post-procedure (p ¼ 0.84).
Only 6 (4.8%) and 5 (4.3%) side branches had TIMI
ﬂow decrease by $1 grade after BVS and CoCr-EES,
respectively (p ¼ 0.82).
DISCUSSION
In the ABSORB China randomized trial, BVS
was noninferior to CoCr-EES for the primary end-
point of angiographic in-segment LL at 1 year
(Table 4). Other angiographic in-segment measures
TABLE 4 1-Year In-S
Intention-to-Treat Po
Per-treatment-evaluab
population, n
In-segment LL, mm
(per subject)*
In-segment LL, mm
Intention-to-treat popu
In-segment LL, mm
(per subject)
In-segment LL, mm
Values are mean  SD un
error. ‡The least-square e
statistic to obtain the p va
CL ¼ conﬁdence limit; G
TABLE 3 Angiographic Results (Core Laboratory), Intention-to-Treat Population
BVS
(n ¼ 238; 251 Lesions)
CoCr-EES
(n ¼ 237; 252 Lesions) Difference (95% CI) p Value
Pre-procedure
Lesion length, mm 14.1  0.32 13.9  0.30 0.2 (0.7 to 1.1) 0.66
RVD, mm 2.81  0.03 2.82  0.03 0.01 (0.09 to 0.07) 0.83
MLD, mm 0.98  0.03 1.01  0.03 0.03 (0.10 to 0.05) 0.48
%DS 65.3  0.82 64.5  0.82 0.8 (1.4 to 3.1) 0.48
Post-procedure
RVD, mm 2.84  0.03 2.85  0.03 0.01 (0.09 to 0.06) 0.73
In-segment MLD, mm 2.30  0.03 2.29  0.03 0.01 (0.07 to 0.08) 0.86
In-device MLD, mm 2.48  0.02 2.59  0.03 0.11 (0.18 to 0.04) 0.002
In-segment %DS 19.0  0.43 19.7  0.52 0.7 (2.0 to 0.6) 0.32
In-device %DS 12.2  0.47 8.7  0.46 3.5 (2.2 to 4.8) <0.0001
In-segment acute gain, mm 1.32  0.03 1.28  0.03 0.04 (0.05 to 0.12) 0.40
In-device acute gain, mm 1.51  0.03 1.59  0.03 0.09 (0.17 to 0.00) 0.04
Total stent/scaffold length, mm 20.6  0.39 20.7  0.35 0.1 (1.2 to 0.9) 0.78
1-year follow-up
RVD, mm 2.80  0.03 2.82  0.03 0.02 (0.10 to 0.06) 0.64
In-segment MLD, mm 2.13  0.03 2.17  0.03 0.03 (0.12 to 0.06) 0.46
In-device MLD, mm 2.27  0.03 2.50  0.03 0.23 (0.31 to 0.14) <0.0001
In-segment %DS 23.5  0.84 23.0  0.92 0.5 (1.9 to 3.0) 0.67
In-device %DS 18.5  0.92 11.3  0.76 7.3 (5.0 to 9.6) <0.0001
In-segment LL, mm 0.18  0.03 0.13  0.03 0.05 (0.02 to 0.13) 0.15
In-device LL, mm 0.23  0.03 0.10  0.02 0.13 (0.06 to 0.20) 0.0001
In-segment ABR (%) 3.9  1.34 2.8  1.13 1.1 (2.3 to 4.5) 0.53
In-device ABR (%) 2.9  1.16 0.75  0.56 2.1 (0.4 to 4.7) 0.10
Values are least square mean  SE unless otherwise indicated. Results of all analyses are adjusted using generalized estimating equations for cases in which 2 lesions were
present in a single patient.
ABR ¼ angiographic binary restenosis; DS ¼ diameter stenosis; LL ¼ late loss; MLD ¼ minimum lumen diameter; RVD ¼ reference vessel diameter; other abbreviations as in
Tables 1 and 2.
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procedure and at follow-up. In-device acute gain
was lower and 1-year in-device LL was greater with
BVS compared with CoCr-EES, although these differ-
ences were small, and in-segment measures were
similar between the 2 devices, as were the 1-year ratesegment Late Loss in the Per-Treatment-Evaluable and
pulations
BVS CoCr-EES
Difference
(Upper 1-Sided
97.5% CL)
Noninferiority
p Value
le 200 195
0.19  0.38 0.13  0.38 0.06 (0.14) 0.01
(GEE) 0.19  0.03† 0.13  0.03† 0.06 (0.14) 0.01‡
lation, n 208 199
0.18  0.39 0.13  0.38 0.05 (0.13) 0.01
(GEE) 0.18  0.03† 0.13  0.03† 0.06 (0.13) 0.01‡
less otherwise indicated. *Study primary endpoint. †Least square mean  standard
stimates from GEE were inputted into the noninferiority test using asymptotic test
lue.
EE ¼ generalized estimating equations; other abbreviations as in Tables 1 and 2.of in-device and in-segment ABR. BVS and CoCr-EES
also demonstrated comparable rates of acute device
and procedural success, with similar 1-year rates of
the PoCE, the device-oriented composite endpoint,
MI, TLR, and scaffold/stent thrombosis. All-cause
mortality was signiﬁcantly lower at 1 year with BVS
compared with CoCr-EES, which although likely due
to chance, is again reassuring for the safety of BVS.
In accordance with China regulatory guidance,
ABSORB China was designed with in-segment LL as
the primary endpoint, a well-accepted surrogate of
the clinical endpoint of ID-TLR (12–14). Indeed,
ABSORB China is the ﬁrst randomized ABSORB trial
powered to test this as a primary endpoint. In-
segment LL is a robust measure of clinical effective-
ness as it accounts for restenosis both within the stent
as well as the peristent margins where issues may
arise due to mismatch of the device and balloon, drug
diffusion effects, and others (14). The mean 1-year in-
segment LL for CoCr-EES in this trial (0.13 mm) is
similar to that reported for CoCr-EES in the SPIRIT III
trial at 8 months (0.14 mm) (11), and more recently
for the platinum chromium everolimus-eluting stent
at 9 months (0.20 mm) from the contemporary
CENTRAL ILLUSTRATION Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With CAD:
Late Loss Distribution in the Intention-to-Treat Population
 Gao, R. et al. J Am Coll Cardiol. 2015; 66(21):2298–309.
Cumulative frequency distribution for 1-year in-segment (A) and in-device (B) late loss. Summary data on the basis of generalized estimating
equations analysis, and presented as least square mean  SE. BVS ¼ bioresorbable vascular scaffold; CI ¼ conﬁdence interval; CoCr-EES ¼
cobalt-chromium everolimus-eluting stent; Diff ¼ difference.
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TABLE 5 1-Year Clinical Outcomes (Intention-to-Treat Population)
BVS (n ¼ 238) CoCr-EES (n ¼ 237) Difference (95% CI) p Value*
Composite endpoints†
DMR (PoCE) 8.0 (19/238) 9.7 (23/237) 1.7 (7.0 to 3.5) 0.51
TVF 4.2 (10/238) 5.9 (14/237) 1.7 (5.9 to 2.40) 0.40
MACE 3.8 (9/238) 4.2 (10/237) 0.4 (4.3 to 3.3) 0.81
TLF (DoCE) 3.4 (8/238) 4.2 (10/237) 0.9 (4.6 to 2.8) 0.62
Cardiac death or MI 2.1 (5/238) 2.1 (5/237) 0.0 (3.0 to 3.0) 1.00
Individual component endpoints†
All-cause death 0.0 (0/238) 2.1 (5/237) 2.1 (4.4 to 0.1) 0.03
Cardiac death 0.0 (0/238) 1.3 (3/237) 1.3 (3.7 to 0.5) 0.50
All MI 2.1 (5/238) 1.7 (4/237) 0.4 (2.4 to 3.3) 1.00
Q-wave MI 0.8 (2/238) 0.0 (0/237) 0.8 (0.9 to 3.0) 0.50
Non–Q-wave MI 1.3 (3/238) 1.7 (4/237) 0.4 (3.1 to 2.2) 0.72
TV-MI 1.7 (4/238) 0.8 (2/237) 0.8 (1.6 to 3.5) 0.69
Q-wave MI 0.8 (2/238) 0.0 (0/237) 0.8 (0.9 to 3.0) 0.50
Non–Q-wave MI 0.8 (2/238) 0.8 (2/237) 0.0 (2.3 to 2.3) 1.00
All TLR 2.9 (7/238) 3.0 (7/237) 0.0 (3.4 to 3.4) 0.99
ID-TLR 2.5 (6/238) 2.1 (5/237) 0.4 (2.6 to 3.5) 0.77
Non–ID-TLR 0.4 (1/238) 0.8 (2/237) 0.4 (2.6 to 1.6) 0.62
All TVR 3.8 (9/238) 5.1 (12/237) 1.3 (5.3 to 2.6) 0.50
ID-TVR 2.9 (7/238) 3.8 (9/237) 0.9 (4.5 to 2.6) 0.61
Non–ID-TVR 0.8 (2/238) 1.7 (4/237) 0.9 (3.5 to 1.6) 0.45
All revascularization 6.7 (16/238) 7.2 (17/237) 0.5 (5.2 to 4.3) 0.85
ID revascularization 5.7 (13/238) 5.5 (13/237) 0.0 (4.3 to 4.3) 0.99
Non-ID revascularization 1.3 (3/238) 2.1 (5/237) 0.9 (3.7 to 1.8) 0.50
Scaffold/stent thrombosis‡
All (0–365 days) 0.4 (1/238) 0.0 (0/232) 0.4 (1.2 to 2.3) 1.00
Deﬁnite 0.0 (0/238) 0.0 (0/232) 0.0 (1.6 to 1.6) 1.00
Probable 0.4 (1/238) 0.0 (0/232) 0.4 (1.2 to 2.3) 1.00
Acute (#1 day) 0.0 (0/238) 0.0 (0/236) 0.0 (1.6 to 1.6) 1.00
Subacute (>1–30 days) 0.4 (1/238) 0.0 (0/236) 0.4 (1.2 to 2.3) 1.00
Late (31–365 days) 0.0 (0/238) 0.0 (0/232) 0.0 (1.6 to 1.6) 1.00
Values are % (n/N) unless otherwise indicated. *The 2-sided p value based on Pearson’s chi-square test was used when Cochran’s rule was met; otherwise, the Fisher exact test
was used. †The end of the 1-year follow-up window was 393 days. The denominators exclude subjects who were lost to follow-up or terminated during each speciﬁc time
interval in whom no DMR event had occurred. ‡The denominators exclude subjects who were lost to follow-up or terminated during each speciﬁc time interval in whom no
speciﬁc ST event had occurred.
DMR ¼ all-cause death, myocardial infarction, or any revascularization; DoCE ¼ device-oriented composite endpoint; ID ¼ ischemia driven; MACE ¼ major adverse cardiac
events (cardiac death, myocardial infarction, or ischemia-driven target lesion revascularization); MI¼myocardial infarction; PoCE¼ patient-oriented composite endpoint; TLF¼
target lesion failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization); TVF ¼ target vessel failure (cardiac death, target
vessel myocardial infarction, or ischemia-driven target vessel revascularization); TLR ¼ target lesion revascularization; TV-MI ¼ target vessel myocardial infarction; TVR ¼
target vessel revascularization; other abbreviations as in Tables 1 and 2.
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limus-Eluting Stents with Everolimus-Eluting Bio-
resorbable Vascular Scaffold) randomized trial (15).
The mean 1-year in-segment LL for BVS in the present
trial (0.19 mm) is less than the 0.30 mm mean in-
segment LL with BVS at 9 months in EVERBIO II trial,
which enrolled an all-comers population (15).
Despite the similar 1-year in-segment angiographic
measures with BVS and CoCr-EES in the present
study, the mean in-device LL was greater with BVS
than with CoCr-EES (0.23 mm vs. 0.10 mm, respec-
tively). Conversely, no signiﬁcant difference in the
mean in-device LL was noted between BVS and
metallic DES at 9 months in the EVERBIO II trial
(0.28 mm vs. 0.25 mm, respectively) (15). Thisdiscordance may be due to differences in patient and
lesion characteristics, different procedural tech-
niques, and possibly, timing of angiographic follow-
up between the 2 studies. Nonetheless, given their
absolute magnitude, the differences in 1-year in-
device (and in-segment) LL in the present study be-
tween BVS and CoCr-EES are not likely to be clinically
meaningful. Pocock et al. (14) demonstrated that
when the absolute 1-year in-segment LL is <0.3 mm
and the in-stent LL is <0.4 mm, TLR rates are very
low, with further reductions in LL unlikely to reduce
clinical restenosis. As also predicted by Pocock et al.
(14), the low 1-year in-device and -segment LL in the
BVS arm from the present study (0.23 and 0.18 mm,
respectively) were associated with low rates of
FIGURE 2 Time-to-Event Curves for TLF and its Components in the Intention-to-Treat Population
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2307in-device and -segment ABR (2.9% and 3.9%, respec-
tively) and 1-year ID-TLR (2.5%), comparable to the
rates of in-device and -segment ABR (0.8% and 2.8%,
respectively) and ID-TLR (2.1%) observed with CoCr-
EES.
The ﬁrst-generation BVS has thicker struts and a
larger crossing proﬁle than contemporary metallic
DES. Nevertheless, issues with deliverability and
tracking of BVS were not observed in the present
study, with high rates of acute device and procedural
success achieved in the present and prior ABSORB
studies, comparable to CoCr-EES in noncomplex
lesions (8,16). Aggressive pre-dilation was recom-
mended, and post-dilation was performed at a higherrate with BVS than CoCr-EES, which may have helped
achieve high rates of acute procedural success with
only a 2.0% bailout rate. Nonetheless, improvements
in implantation technique (e.g., routine post-dilation
or more frequent use of intravascular imaging guid-
ance, which was rarely used in the present study) and
device iterations (thinner struts with reduced recoil)
may further improve deliverability and angiographic
and clinical outcomes, especially in complex lesions.
In the present study, the 1-year rates of device-
and patient-oriented composite outcomes were
comparable between BVS and CoCr-EES. Similar re-
sults were reported from the ABSORB II European
multicenter randomized trial (8). Acknowledging
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In patients undergoing PCI,
the safety and angiographic efﬁcacy of the BVS was
similar at 1 year to the CoCr-EES metallic DES.
TRANSLATIONAL OUTLOOK: Additional studies
are required to assess longer-term clinical outcomes
following deployment of BVS in patients with com-
plex coronary lesions compared with more conven-
tional stent devices.
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study examinations, ABSORB China and ABSORB II
showed similar performance of BVS in Chinese and
European patients. In both trials (480 and 501 ran-
domized patients, respectively), BVS and CoCr-EES
had comparable rates of PoCE, target lesion failure,
cardiac death, TV-MI, all MI, and ID-TLR. Moreover,
despite the wider struts of BVS compared with CoCr-
EES, similar rates of periprocedural myonecrosis
were noted with both devices in both trials, regard-
less of whether a threshold of 3, 5, or 10 CK-MB was
used. By core laboratory analysis, reductions in side
branch TIMI ﬂow were not more common after BVS
than the thinner strutted CoCr-EES. Further study is
required to determine whether this observation holds
in more complex bifurcations or with larger side
branches than were enrolled in these studies.
Stent and scaffold thrombosis rates were very low
in our trial. Only 1 patient experienced a probable
scaffold thrombosis, and no deﬁnite thromboses
occurred. The cumulative 1-year scaffold thrombosis
rate for BVS was slightly lower in our study than that
in ABSORB II (0.4% vs. 0.9%) (8). These results should
be interpreted cautiously given the low incidence of
device thrombosis and the modest sample size of both
studies.
STUDY LIMITATIONS. ABSORB China was an open-
label trial (in contrast to other DES studies), and
some degree of bias cannot be excluded. However, the
effect of potential bias on outcomes was minimized by
use of an independent clinical events committee to
adjudicate events on the basis of original source doc-
uments and an independent angiographic core labo-
ratory using established algorithms and criteria.
Intravascular imaging was utilized in only 2 patients in
our study, and additional studies are required to
determine if routine use of either intravascular ultra-
sound or optical coherence tomography would
improve BVS outcomes. The lesions enrolled were
relatively noncomplex, and follow-up duration to date
is short (only 1 year). BVS is still undergoing activebioresorption at 1 year, a process which is not complete
untilw3 years. Ongoing follow-up is required to assess
the long-term effect of BVS on clinical outcomes.
Angiographic follow-up was performed in temporal
proximity to the 1-year clinical follow-up, and an effect
of the oculostenotic reﬂex cannot be excluded (17).
Finally, the present study was not powered to detect
changes in clinical outcomes between the groups, and
the signiﬁcantly lower rate of all-cause mortality with
BVS compared with CoCr-EES may represent type I
error. Larger investigations, such as the ongoing
ABSORB IV trial (NCT01751906), are required to
determine whether there are meaningful early or late
clinical differences between these 2 devices.
CONCLUSIONS
In the present multicenter randomized trial, BVS was
noninferior to CoCr-EES for the primary endpoint of
in-segment late loss at 1 year.
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